Side-by-side financials for FATE and AMGN. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | FATE | AMGN |
|---|---|---|
| Market cap | - | $191.70 B |
| US-listed rank | - | #79 |
| Revenue (latest FY) | $6.65M | $36.75B |
| Net income (latest FY) | -$136.31M | $7.71B |
| Net margin | -2051.1% | 21.0% |
| P/E (trailing FY) | - | 24.9 |
| SEC filings | 827 | 1,011 |
In their latest fiscal years, FATE THERAPEUTICS INC reported $6.65M in revenue while AMGEN INC reported $36.75B.
Full pages: FATE THERAPEUTICS INC and AMGEN INC, or browse the full rankings.